The FDA cleared SPR Therapeutics' Sprint single-lead endura and dual-lead extensa peripheral nerve stimulation systems.
Here are five insights:
1. The Sprint System is the only FDA-cleared percutaneous PNS system indicated for up to 60 days of therapy in the back and/or extremities for chronic and acute pain.
2. The Sprint System is also the industry’s only PNS platform with dual-led capability. The dual-lead capability allows physicians to implant two leads connected to a single wearable pulse generator.
3. Physicians can place the Sprint PNS system leads without surgery, incisions, tissue destruction or anesthesia during outpatient procedures.
4. Preliminary results from a multicenter study evaluating Sprint showed the therapy was associated with significant reduction in chronic post-amputation pain among two-thirds of subjects, after eight weeks of treatment. Four of five patients reported enduring and significant pain relief.
5. SPR Therapeutics aims to advance the early use of neurostimulation as a non-opioid alternative.